top of page


Updated: Apr 7, 2022

The Body Protective Compound


  • protective effect on intestinal track and stomach

  • improved healing of joints and bones

  • beneficial effects against stomach ulcers, fistulas, and inflammatory conditions

  • improved tendon outgrowth

  • cell survivial

  • promoting liagament and tendon recovery

  • direct healing of tendon bone

  • neurtralizes damage in the gut lining from Non-steriodal anti-inflammatory drugs (e.g. tylenol)

  • reverse damage caused by IBS within several days

  • reverses sytematic corticosteroid damage muscle recovery

  • successful in curing periodontal disease when regularly administered

  • anabolic healing properties for both lower and upper gastrointestinal tract


Typically injected subcutaneously, can also be injected intramuscularly. Despite having systematic effect it is recommended to inject close to the effected body part. It has been used in studies between 1-10 mcg per kg of body weight. For an average person this means between 200mcg and 800mcg daily. BPC-157 is known to start noticeably working 24-48 hrs. Typically, it is used for 1 month or until the injury is healed, after the first month cease use for 2 weeks and then continue until injury is healed.

Buy Research Quality BPC-157 from USA here.

Buy Research Quality BPC-157 from Canada here


BPC-157 was discovered in late 1990's and has been extensively used in research since, including in vivo (human and animal) and in-vitro studies. BPC-157, Body Protecting Compound, is a peptide chain that was developed from a protective gastric protein, however is considered a synthetic compound as its particular sequence is not found in nature. It's name, BPC was given due to its protective actions and ability to heal injuries and decrease fatigue of the central nervous system due to intensive excercise and stress.

Mechanism of Action

BPC-157 increases gene expressions in charge of cytokines, collagen formation, growth factor production and repairing of intestinal anastomosis. It also produces a reaction with the nitric oxide system producing a protective effect of endothelial tissue.

In Studies

Healing Properties

A study conducted by Seiwerth et al. in 2021 looked to define the healing properties of BPC-157, a while knownantiulcer "body protective compound" stable gastric pentadecapeptide. They noted in clinical trials no toxicity (LD50) has been determined. They found in animals studies and from human trials on BPC-157, that it simutaneously cures both cutaneous and other tissue wounds. The other tissues include colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, and rectovaginal. Furthermore, by understanding the mechanism by which BPC-157 can heal wounds, they determined BPC-157 to be an effective solution to counteracting bleeding disorders, produced by amputation, and/or anticoagulants application, and also may be able to prevent or eliminate/counteract both arterial and venous thrombosis.

Spinal Cord Injuries

Perovic et al., 2019, investigated the effects of BPC-157 on the healing of spinal cord injury using a rat model. Administering BPC-157 after transection in the sciatic nerve, brain injury after concussion, and in severe encephalopathies, there is a positive therapeutic effect. In their model the rats that recieved BPC 157 exhibited better motor function of their tail, while axional and neuronal necrosis, demyelination, and cyst formation were counteracted. This suggests BPC-157 may be a plausible agent in healing spinal cord injuries.

Multiple Sclerosis and Inflammatory Bowel Disease

A study by Klicek et al., 2013, investigated the potential of BPC-157 as a therapeutic agent in both multiple sclerosis and inflammatory bowel disease. Previous studies had linked BPC-157 to inflammatory bowel disease and multiple sclerosis, thus they predicted that administration of BPC 157 may affect the outcome of both these diseases. They used two rat models, each with a control group. They used cysteamine and colon-colon anastomisis rat model and the control group recieved saline. They found that the control groups could not heal cysteamine colitis and colon-colon anastomosis,where the BPC-157 group had induced healing of both. The multiple sclerosis suited model found that the rats in the control group exhibited stronger and more accelerated damaging with nerve damage appearing in the brain (most prominently in corpus callosum, laterodorsal thalamus, nucleus reunions, anterior horn motor neurons). Whereas, the BPC 157-cuprizone rats had consistently less nerve damage in all damaged areas, especially in the areas that were most affected in teh control group. This data suggestst that BPC-157 may have strong therapeutic effects for pateints with either multiple sclerosis or inflammatory bowel disease.


All information found on, and its associated blog is intended for informational and entertainment use only. Vantanex Corp does not provide medical advice. Vantanex Corp tries to provide the most recent and up-to-date research however can make no guarantees this is the case. Vantanex Corp does not condone the use of illegal drugs or the use of drugs for unintended purposes. Before taking any medication, over-the-counter drugs or medication, seek medical advice from a medical professional. No liability will be assumed for the use of these articles, the contained information is not medical advice.

For more information on buying BPC-157 read Vantanex's Terms & Conditions

Recent Posts

See All


bottom of page